August 14th 2025
In this Q&A, Rohit Nambisan, CEO of Lokavant, and Jonathan Crowther, head of predictive analytics, Pfizer, explore how AI is transforming study feasibility, regulatory review, and trial execution.
Recruitment & Consent in India
November 1st 2006India continues to gain the attention of pharmaceutical companies looking for a place to conduct clinical trials because of the country's reputation for fast subject recruitment rates. But as Jane Barrett reveals, sometimes the country's clinical trial participants are more uninformed than informed.
Subject Diversity Is Good for the Business of Medicine
April 1st 2005With the advent of personalized medicine and purported "race-based therapies" such as BilDil in the news, it is time the pharmaceutical industry makes a more concerted effort to engage racial and ethnic minority groups and the rural poor in clinical research.